Radioiodine treatment in Graves' disease: Is there a therapeutic standard?

被引:0
|
作者
Moser, E
机构
来源
ZENTRALBLATT FUR CHIRURGIE | 1997年 / 122卷 / 04期
关键词
Graves' disease; radioiodine treatment;
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
This review article will come to a positive answer to the question entitled. The good experiences within more than 50 years were able to define commonly accepted standards concerning the following items: therapeutic aim, indications, contraindications, pretreatment, dose concept, assessment of radioactivity, follow-up. The broad consensus among experts when to apply medical treatment, surgery or radioiodine in this special disease was one of the reasons that the nuclear medicine treatment is accepted more and more. By this, the patients have to wait for many months to become treated on an in-patient basis, as it is mandatory in Germany. In the current health care scenery it is absolutely unrealistic to demand an increasing number of radioiodine beds. Facing this fact the guidelines of applying radioiodine which are extremely restrictive in Germany have to be modified as proposed by the National Commission on Radiation Protection.
引用
收藏
页码:227 / 230
页数:4
相关论文
共 50 条
  • [41] Results of a risk adapted and functional radioiodine therapy in Graves' disease
    Dunkelmann, S
    Neumann, V
    Staub, U
    Groth, P
    Künstner, H
    Schümichen, C
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2005, 44 (06): : 238 - 242
  • [42] Worsening of endocrine ophthalmopathy after radioiodine therapy in Graves' disease?
    Weigand, A
    Hinzpeter, B
    Schicha, H
    NUKLEARMEDIZIN, 1998, 37 (07) : 234 - 238
  • [43] Onset age is associated with outcome of radioiodine therapy in Graves′ disease
    Yamashita, Y
    Yamane, K
    Tamura, T
    Okubo, M
    Kohno, N
    ENDOCRINE JOURNAL, 2004, 51 (02) : 127 - 132
  • [44] Factors influencing the success of radioiodine therapy in patients with Graves' disease
    Sfiligoj, Dasa
    Gaberscek, Simona
    Mekjavic, Polona Jaki
    Pirnat, Edvard
    Zaletel, Katja
    NUCLEAR MEDICINE COMMUNICATIONS, 2015, 36 (06) : 560 - 565
  • [45] Quality of life and decision regret in patients with late-hypothyroidism after radioiodine treatment for Graves' disease
    Li, Yue
    Yang, Tianyu
    Ju, Linjun
    Feng, Yuyue
    Chen, Zheng
    Xiang, Xing
    Zhu, Tao
    Pang, Hua
    Wang, Zhengjie
    CLINICAL ENDOCRINOLOGY, 2024, 100 (01) : 87 - 95
  • [46] 123I Scintigraphy Mirror Image of Graves Disease Induced by Radioiodine Treatment for Toxic Adenoma
    Lugat, Alexandre
    Drui, Delphine
    Bach-Ngohou, Kalyane
    Guillot, Pascale
    Mourrain-Langlois, Emmanuelle
    Kraeber-Bodere, Francoise
    Ansquer, Catherine
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (02) : E197 - E198
  • [47] STANDARDIZED RADIOIODINE THERAPY IN GRAVES-DISEASE - THE PERSISTENT EFFECT OF THYROID WEIGHT AND RADIOIODINE UPTAKE ON OUTCOME
    DEBRUIN, TWA
    CROON, CDL
    DEKLERK, JMH
    VANISSELT, JW
    JOURNAL OF INTERNAL MEDICINE, 1994, 236 (05) : 507 - 513
  • [48] TSHR as a therapeutic target in Graves' disease
    Smith, Terry J.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (04) : 427 - 432
  • [49] Radioiodine uptake after monotherapy with potassium iodide in patients with Graves' disease
    Mikura, Kentaro
    Noh, Jaeduk Yoshimura
    Watanabe, Natsuko
    Aida, Azusa
    Yoshimura, Ran
    Kinoshita, Aya
    Suzuki, Ai
    Suzuki, Nami
    Fukushita, Miho
    Matsumoto, Masako
    Yoshihara, Ai
    Sugino, Kiminori
    Ito, Koichi
    ENDOCRINE JOURNAL, 2023, 70 (05) : 541 - 549
  • [50] Incidence of radioiodine induced Graves' disease in patients with multinodular toxic goiter
    Meller, J.
    Siefker, U.
    Hamann, A.
    Huefner, M.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2006, 114 (05) : 235 - 239